BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Acquires Akero Therapeutics for $5.2B, Boosting Liver Disease Drug Development
Novo Nordisk Acquires Akero Therapeutics for $5.2B, Boosting Liver Disease Drug Development
6
3
BTCCSquare news:
Akero Therapeutics (AKRO) surged 19% following its acquisition by Novo Nordisk (NVO) in a deal worth up to $5.2 billion. The Danish pharmaceutical giant will pay $54 per share upfront—a 16.2% premium to Akero's last close—with an additional $6 per share contingent on U.S. approval of its experimental MASH drug, efruxifermin, by 2031.
The transaction, unanimously approved by Akero's board, aligns with Novo's strategic push into metabolic diseases. Efruxifermin targets liver fibrosis and cirrhosis, complementing Novo's diabetes and obesity portfolio. "MASH destroys lives silently," underscoring the unmet need for therapies addressing this progressive condition.
By:
